sutimlimab

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Cold Agglutinin Disease

Drug Information

Target Indication

Cold Agglutinin Disease

Clinical Trial

Last updated: 12/12/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Regulatory Approvals

EMA11/15/2022

Enjaymo

Enjaymo is indicated for the treatment of haemolytic anaemia in adult patients with cold agglutinin disease (CAD).

Orphan

Drug Science

Mechanism of action & safety profile

Developer

SNY

Sanofi

Related Pipeline

Sleep Initiation and Maintenance Disorders

Hemophilia A

Ulcerative Colitis

Alzheimer Disease

Influenza

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts